How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,757 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1741. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. (PubMed)

Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Data on genome-wide surveys for chromosome aberrations in primary cutaneous T-cell lymphoma (CTCL) are limited.To investigate genetic aberrations in CTCL.We analysed 18 cases of Sézary syndrome (SS) and 16 cases of mycosis fungoides (MF) by comparative genomic hybridization (CGH) analysis, and correlated findings with the results of additional

2002 British Journal of Dermatology

1742. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. (PubMed)

Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Extracorporeal photopheresis (ECP) is an effective treatment for cutaneous T-cell lymphoma. Controversy has arisen regarding its ability to improve survival rates in Sézary syndrome (SS). We describe our experience with ECP in the treatment of SS and erythrodermic mycosis fungoides, with particular (...) emphasis on early predictors of long-term outcome.We included 17 patients (15 with SS and 2 with erythrodermic mycosis fungoides) who received ECP as initial treatment. Four of these patients were moribund on presentation (Eastern Cooperative Oncology Group Performance Status score, 4) and underwent only 1 to 2 cycles of ECP. The median survival was 56 months for the 11 patients with SS and an Eastern Cooperative Oncology Group Performance Status score of less than 4. If all 15 patients with SS

2002 Archives of Dermatology

1743. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. (PubMed)

The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. For nearly two decades it has been suspected that the cutaneous T cell lymphoma, mycosis fungoides (MF), and its leukemic variant, the Sézary syndrome, are caused by the human T lymphotropic virus (HTLV-I/II). Arguments against this concept included the finding that only a small number of MF patients have antibodies to HTLV-I/II and that attempts to detect proviral

Full Text available with Trip Pro

1995 Journal of Clinical Investigation

1744. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. (PubMed)

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Patterns of mycosis fungoides incidence and associated mortality in the United States were evaluated.Data were taken from the Surveillance, Epidemiology, and End Results cancer registry program and the National Center for Health Statistics.The incidence rate from 1973 through 1992 was 0.36/10(5) person-years. The age-adjusted incidence rate ratio of Blacks to Whites was 1.7; that of Asians to Whites (...) was 0.6. There was no evidence of increasing incidence rates during the period 1983 through 1992. Mortality rates declined steadily from 1979 to 1991 and were less heterogeneous geographically than incidence rates. Mortality rate patterns with age, sex, and race were similar to the corresponding incidence patterns.The incidence rate of mycosis fungoides has stabilized and the mortality rate has declined. For unknown reasons, the disorder varies greatly among demographic and geographic subgroups.

Full Text available with Trip Pro

1999 American Journal of Public Health

1745. Cell Surface Differentiation Antigens of the Malignant T Cell in Sezary Syndrome and Mycosis Fungoides (PubMed)

Cell Surface Differentiation Antigens of the Malignant T Cell in Sezary Syndrome and Mycosis Fungoides Using a panel of monoclonal antibodies and rabbit heteroantisera, we have studied the cell surface markers of peripheral blood (PB) Sezary cells from six patients with mycosis fungoides or Sezary syndrome, disease grouped within the spectrum of cutaneous T cell lymphomas (CTCL). Furthermore, we have studied two cell lines (Hut 78 and Hut 102) derived from malignant Sezary T cells from CTCL

Full Text available with Trip Pro

1981 Journal of Clinical Investigation

1746. DNA Content Analysis by Flow Cytometry and Cytogenetic Analysis in Mycosis Fungoides and Sézary Syndrome: DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS (PubMed)

DNA Content Analysis by Flow Cytometry and Cytogenetic Analysis in Mycosis Fungoides and Sézary Syndrome: DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS Flow cytometric (FCM) analysis of DNA content was performed on 82 lymph node and peripheral blood specimens from 46 patients with mycosis fungoides and the Sézary syndrome. Overall, 32 of the 46 patients (70%) had aneuploidy detected by FCM. Aneuploidy was present in 63% of the patients at the time of diagnosis before systemic therapy

Full Text available with Trip Pro

1980 Journal of Clinical Investigation

1747. Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. (PubMed)

Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. 2341572 1990 06 25 2018 11 13 0021-9746 43 4 1990 Apr Journal of clinical pathology J. Clin. Pathol. Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. 347 Habboush H W HW Lucie N P NP Mackie R M RM Ashworth J J Turbitt M M eng Case Reports Letter England J Clin Pathol 0376601 0021-9746 AIM IM Hair Diseases complications Humans Leukemia, Myeloid, Acute etiology Male Middle Aged Mycosis Fungoides complications

Full Text available with Trip Pro

1990 Journal of Clinical Pathology

1748. Intraocular involvement with subretinal pigment epithelium infiltrates by mycosis fungoides. (PubMed)

Intraocular involvement with subretinal pigment epithelium infiltrates by mycosis fungoides. We report a case of intraocular mycosis fungoides in a 48-year-old man. The patient presented with decreased visual acuity, white subretinal lesions, and vitritis. Post-mortem histopathology revealed malignant T cell infiltrates consistent with mycosis fungoides in the retina, vitreous, and between the retinal pigment epithelium (RPE) and Bruch's membrane Focal atrophy of the RPE, along with the sub-RPE

Full Text available with Trip Pro

1991 The British journal of ophthalmology

1749. Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides. (PubMed)

Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides. A severe non-dose related skin eruption attributable to treatment with captopril was recently reported: this is distinct from the dose related rashes that have been widely described. Ultrastructural and immunohistochemical studies were carried out to determine in detail the histological features of this eruption: the histological appearances were similar to those found in early (...) mycosis fungoides, so that this disease was erroneously diagnosed in one case. Unlike most other complications resulting from treatment with Captopril, an indistinguishable rash can result from treatment with enalapril, a newer angiotensin converting enzyme inhibitor.

Full Text available with Trip Pro

1986 Journal of Clinical Pathology

1750. Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. (PubMed)

Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. 2503190 1989 09 15 2018 11 13 0959-8138 298 6689 1989 Jun 24 BMJ (Clinical research ed.) BMJ Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. 1713 Braathen L R LR Stavem P P eng Case Reports Journal Article England BMJ 8900488 0959-8138 0 Interferon Type I 0 Recombinant Proteins AIM IM Anemia, Hemolytic, Autoimmune chemically induced Humans (...) Interferon Type I adverse effects Male Middle Aged Mycosis Fungoides drug therapy Recombinant Proteins Skin Neoplasms drug therapy 1989 6 24 1989 6 24 0 1 1989 6 24 0 0 ppublish 2503190 PMC1836763 Br J Dermatol. 1983 Jul;109(1):49-56 6860571 Clin Exp Immunol. 1983 Oct;54(1):1-13 6193915 Br J Dermatol. 1984 Apr;110(4):495-7 6608954 Ann Intern Med. 1984 Oct;101(4):484-7 6332565 Ann Intern Med. 1986 Aug;105(2):306 3729223 Lancet. 1985 Jul 13;2(8446):100-1 2861513 JAMA. 1985 Sep 13;254(10):1353-4 4021013

Full Text available with Trip Pro

1989 BMJ : British Medical Journal

1751. Transfer factor therapy in mycosis fungoides: a double-blind study. (PubMed)

Transfer factor therapy in mycosis fungoides: a double-blind study. Sixteen patients with mycosis fungoides (MF) were given either active transfer factor (TF) or heat-inactivated TF as additional therapy to topical nitrogen mustard or PUVA. The TF was prepared from non-selected healthy blood donors. The clinical evaluation after 2 years of therapy showed that among 8 patients treated with active TF, none went into complete remission of their disease 4 patients had partial remission, one (...) levels of T lymphocytes in peripheral blood. A temporary increase was observed in the total number of T lymphocytes in patients after one month of treatment with active TF. After one year the T lymphopenia had disappeared in both groups. The mitogen reactivity of lymphocytes was found to be normal (PHA, PWM) or somewhat reduced (Con A). It is concluded that under the conditions employed in this trial, TF was not able to prevent progression of early mycosis fungoides, when viewed over a period of 2

1982 Acta dermato-venereologica Controlled trial quality: uncertain

1752. Intralesional interferon in the treatment of early mycosis fungoides. (PubMed)

Intralesional interferon in the treatment of early mycosis fungoides. Twelve patients with early mycosis fungoides were enrolled in a randomized, double-blind, placebo-controlled study. Isolated plaques were injected three times a week with recombinant alpha 2-interferon in nine patients and with the vehicle in three patients. Two additional plaques were evaluated in each patient; one was left untreated, and another was treated topically with either placebo ointment or betamethasone ointment

1985 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

1753. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. (PubMed)

Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. A two-part clinical trial was conducted to determine the therapeutic efficacy of recombinant interferon alfa-2b in plaque-phase mycosis fungoides. In an initial randomized double-blind study, each of six patients had two representative plaques injected intralesionally with 1 X 10(6) U of recombinant interferon alfa-2b per site and two control plaques injected with placebo three

1987 Archives of Dermatology Controlled trial quality: uncertain

1754. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. (PubMed)

Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. Mycosis fungoides (MF) belongs to cutaneous T-cell lymphoma and is clinically divided into 3 stages: patch, plaque, and tumor stage. Thymus and activation-regulated chemokine (TARC/CCL17) is a member of the CC chemokines and is a chemoattractant for CC chemokine receptor 4 (CCR4)- and CC chemokine receptor 8 (CCR8)-expressing cells.In this study, we

2003 Journal of American Academy of Dermatology

1755. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. (PubMed)

Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. In early stages of the disease many different clinicopathologic variants have been observed.We report 6 patients with early manifestations of MF characterized by the sole presence of papules which, unlike the papules of lymphomatoid papulosis, did not show a tendency for spontaneous resolution. Histologic examination confirmed the diagnosis

2005 Journal of American Academy of Dermatology

1756. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. (PubMed)

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Histological evidence of lymph node involvement is associated with a poor prognosis in patients with cutaneous T-cell lymphoma (CTCL).To determine whether T-cell receptor (TCR) gene analysis is of prognostic relevance in CTCL.TCR gene analysis was performed on lymph node specimens from 60 patients (...) with mycosis fungoides (MF) and Sézary syndrome (SS) using a highly sensitive polymerase chain reaction (PCR)/single-strand conformational polymorphism analysis and results were correlated with skin, overall clinical and histological lymph node stages.The frequency with which a T-cell clone was detected in lymph node samples from patients with MF increased with skin stage, overall clinical stage and with the degree of histological involvement: six of 19 patients with uninvolved lymph nodes or limited

2006 British Journal of Dermatology

1757. Anetodermic mycosis fungoides: a new clinicopathological variant of mycosis fungoides. (PubMed)

Anetodermic mycosis fungoides: a new clinicopathological variant of mycosis fungoides. Mycosis fungoides is the most common type of primary cutaneous T-cell lymphoma. Several rare clinicopathological variants of mycosis fungoides have been described. Patients with these variants often also have classic mycosis fungoides at other sites of the body. Anetoderma is a cutaneous disorder in which multiple, oval lesions or atrophic plaques with wrinkled surface develop progressively due to loss (...) of the dermal elastic tissue. Primary anetoderma occurs when there is no underlying associated disease and it arises on clinically normal skin, whereas secondary anetoderma appears in the same site as a previous specific skin lesion. There is a large list of heterogeneous dermatoses associated with secondary anetoderma. Two patients developed areas of secondary anetoderma on plaque stage lesions of mycosis fungoides. The lesions consisted of exophytic nodular lesions, with very soft consistency on palpation

2007 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>